Volastra Therapeutics

Volastra Therapeutics

  • Founded: 2020
  • Location: New York, NY
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Multiple cancers
  • Drug types: ONC
  • Lead product: Sovilnesib
  • Product link: https://www.volastratx.com/pipeline/
  • Funding: $60M A Mar 2023; $32M seed Apr 2021; $12M seed Sep 2020
  • Investors: Vida Ventures, Catalio Capital Management, Polaris Partners, Droia Ventures, Arch Venture Partners, Quark Venture, Cornell University



job board

Short description:

Therapies for the treatment of metastatic cancers

Drug notes:

VLS-1488 Clin0 oncology; 2 undisclosed programs RD oncology

Long description:

Volastra Therapeutics is developing drugs that target a vulnerability of cancer cells - chromosomal instability, or CIN. CIN is present in 60-80% of cancers and is associated with poor survival in many patients. By using their proprietary CINtech platform that incorporates cancer biology, data sciences and medicinal chemistry, Volastra is turning a deep biological understanding of CIN into life-saving therapies. The tools Volastra is using range from CIN CRISPR screen, CIN imaging and genomics to molecular structure-activity analysis. Volastra is initially focusing on two therapeutic approaches: synthetic lethality and immune activation, with programs in early development.


Volastra Therapeutics
Director/Senior Director, Biostatistics/Biometrics...
New York City, NY|7 days ago
Volastra Therapeutics
Senior Scientist/Associate Director, Bioinformatic...
New York City, NY|8 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com